Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤주영 | * |
dc.date.accessioned | 2022-11-03T16:31:07Z | - |
dc.date.available | 2022-11-03T16:31:07Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 0935-9648 | * |
dc.identifier.issn | 1521-4095 | * |
dc.identifier.other | OAK-32461 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/262881 | - |
dc.description.abstract | Currently, the role of the lysosome, endoplasmic reticulum, or dictyosome in the transcription and translation of programmed cell death ligand 1 (PD-L1) is well revealed, but the role and function of mitochondria in the PD-L1 expression in tumors is still not fully researched, making it hard to offer a novel PD-L1 regulation strategy. In this research, it is newly revealed that mitochondria oxidative phosphorylation (OXPHOS) depression can be used as an effective PD-L1 down-regulation method. To offer an ideal and high-effective tumor mitochondria-targeted OXPHOS depression nanosystem, IR-LND is prepared by conjugating mitochondria-targeted heptamethine cyanine dye IR-68 with mitochondrial complexes I and II depression agent lonidamine (LND), which then further self-assembled with albumin (Alb) to form IR-LND@Alb nanoparticles. By doing this, PD-L1 expression in tumors is selectively and effectively depressed by IR-LND@Alb nanoparticles. As expected, the anti-tumor efficacy of such a PD-L1 depression strategy is superior to conventional anti-PD-L1 monoclonal antibodies. Interestingly, IR-LND can also be served as a novel ideal promising photodynamic therapy (PDT) drug with self-oxygen and self-PD-L1 regulation capacity. All in all, this tumor-selective metabolic reprogramming platform to reactivate immunotherapy and sensitize for PDT effect, would open a new window for mitochondrial immunotherapy for cancer patients. | * |
dc.language | English | * |
dc.publisher | WILEY-V C H VERLAG GMBH | * |
dc.subject | immunotherapy | * |
dc.subject | mitochondria | * |
dc.subject | photodynamic therapy | * |
dc.subject | programmed death ligand-1 | * |
dc.subject | tumor targeting | * |
dc.title | Tumor Selective Metabolic Reprogramming as a Prospective PD-L1 Depression Strategy to Reactivate Immunotherapy | * |
dc.type | Article | * |
dc.relation.issue | 41 | * |
dc.relation.volume | 34 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | ADVANCED MATERIALS | * |
dc.identifier.doi | 10.1002/adma.202206121 | * |
dc.identifier.wosid | WOS:000850605300001 | * |
dc.identifier.scopusid | 2-s2.0-85137536848 | * |
dc.author.google | Liu, Yu | * |
dc.author.google | Zhou, Zaigang | * |
dc.author.google | Hou, Jiting | * |
dc.author.google | Xiong, Wei | * |
dc.author.google | Kim, Heejeong | * |
dc.author.google | Chen, Jiashe | * |
dc.author.google | Zheng, Chunjuan | * |
dc.author.google | Jiang, Xin | * |
dc.author.google | Yoon, Juyoung | * |
dc.author.google | Shen, Jianliang | * |
dc.contributor.scopusid | 윤주영(7403587371) | * |
dc.date.modifydate | 20240118162450 | * |